speb/financial-data huggingface dataset:
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 71235000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 71235000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Minority Interests: -24764000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 1481000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: 0.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 420000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -161414000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Net Income: 2093086000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Net Income: 615075000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 2093086000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 615075000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 2154350000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 622692000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Net Income Discontinuous Operations: -36500000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Net Income Discontinuous Operations: -9098000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 2093086000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 615075000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 2129586000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 624173000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 2524742000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 2117850000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 613594000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Net Interest Income: -101669000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -50960000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: 88276000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 339174000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 405688000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -101669000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -50960000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Other Financing Charges: 1000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: -1000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Net PPE: 1441308000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 1441308000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -1700962000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: -66514000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 9897758000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 9897758000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 191392000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 191392000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 23808000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 23808000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 3153252000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 810422000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Normalized Income: 2180956630.95
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 605828306.17
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 558850000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Operating Income: 2430690000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Operating Income: 565043000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Operating Revenue: 14110851000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 3455671000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 55213530.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 55213530.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: -345015000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 3047183000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 3047183000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 1111963000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 1111963000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 16837439000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 16837439000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 2126323000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 2126323000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -59725000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 452553000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 452553000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 41178000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 41178000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 293294000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 142260000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 1085952000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 280438000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Other Properties: 1441308000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 1441308000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 39961000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 39961000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 3827838000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 3827838000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Payables: 1445978000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Payables: 1445978000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Pretax Income: 2561242000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 676266000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 5208000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Purchase Of Business: 0.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -39100000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -1700962000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 4312145000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 957976000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 429268000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 103119000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 127376000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Share Issued: 55213530.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 55213530.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Special Income Charges: -61073000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 19923000.00
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 7152000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 17375436000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 17375436000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 9897758000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 9897758000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -9702369.05
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 1578306.17
AURIONPRO.NS income_statement (annual, 2026-03-31) — Tax Provision: 406892000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 53574000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.16
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.08
AURIONPRO.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -522846000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Total Assets: 23346642000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 23346642000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 17390234000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 17390234000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Total Debt: 606735000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 606735000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 17446671000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 17446671000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Total Expenses: 11680161000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 2890628000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 5899971000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 5899971000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 10761299000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 10761299000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 674873000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 674873000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 218353000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 218353000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -61073000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 19923000.00
AURIONPRO.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -61073000.00
AURIONPRO.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 19923000.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Treasury Shares Number: 0.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 0.00
AURIONPRO.NS balance_sheet (annual, 2026-03-31) — Working Capital: 7360245000.00
AURIONPRO.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 7360245000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -38680300000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 4268900000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -921300000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Amortization: 3286600000.00
AUROPHARMA.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 3286600000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Assets Held For Sale Current: 791000000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 585938609.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Basic EPS: 45.19
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 28410900000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 6297200000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 35327900000.00
AUROPHARMA.NS cash_flow (annual, 2022-03-31) — Common Stock Dividend Paid: -2637000000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Current Deferred Taxes Liabilities: 580300000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 585938609.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Diluted EPS: 45.19
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 25700000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 151500000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 33545500000.00
AUROPHARMA.NS cash_flow (annual, 2022-03-31) — Gain Loss On Sale Of Business: 26500000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 6803500000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 41043900000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Hedging Assets Current: 320200000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Impairment Of Capital Assets: 1922200000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Interest Income: 316000000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 316000000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Investmentsin Associatesat Cost: 107600000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Investmentsin Joint Venturesat Cost: 2748000000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 7811800000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 79741900000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 1717900000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 1461200000.00
AUROPHARMA.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Outside Changein Cash: -32500000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Inventories: 3402700000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Payable: 6813500000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 1705600000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 12319700000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 26611900000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 1241900000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 1241900000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Research And Development: 652400000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 60200000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 225190100000.00
AUROPHARMA.NS cash_flow (annual, 2022-03-31) — Sale Of Business: 292900000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 14966700000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 21770200000.00
AUROPHARMA.NS cash_flow (annual, 2022-03-31) — Short Term Debt Payments: -26366600000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 118000000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Tradeand Other Payables Non Current: 297700000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Trading Securities: 2260000000.00
AUROPHARMA.NS balance_sheet (annual, 2022-03-31) — Work In Process: 11978400000.00
AUROPHARMA.NS income_statement (annual, 2022-03-31) — Write Off: -22300000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — +Operating Expense: 101798300000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — +Total Revenue: 246171300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 38713100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 44663800000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -55593500000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 4268900000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -1216600000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Amortization: 4112900000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 4112900000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Assets Held For Sale Current: 857600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 618600000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 585938609.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Basic EPS: 32.90
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 41625100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 35920400000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -27204000000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 4246900000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 585900000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 43962900000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 62236300000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -4395300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 25931300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 18031600000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -9267000000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -5753600000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 1087500000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Payable: 7076500000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -4310700000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -10949800000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Changes In Cash: 2234100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Common Stock: 585900000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Common Stock Dividend Paid: -4395300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 268398500000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 48082200000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 118997000000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Assets: 215456700000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 1031600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Debt: 42425600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 43457200000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Deferred Taxes Liabilities: 2116000000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 114937800000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 2005300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Defined Pension Benefit: 45300000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Depreciation: 8332900000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 12445800000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 12445800000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 8332900000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 585938609.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Diluted EPS: 32.90
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 19275000000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 24900000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — EBIT: 27414500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — EBITDA: 39860300000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: -600000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — End Cash Position: 43922700000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 151500000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: 18144100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 37272900000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: -3336500000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -191400000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of Business: 0.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: -132300000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 6624100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Goodwill: 5960700000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 39219200000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 45880400000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 183629500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Gross Profit: 127174300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Hedging Assets Current: 191400000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Held To Maturity Securities: 1511500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Impairment Of Capital Assets: 239600000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Interest Expense: 1289500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 1289500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Interest Income: 1458900000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 1458900000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -1112000000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 1466200000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Inventories Adjustments Allowances: -48800000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Inventory: 85112300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 317013700000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -39777500000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 2281600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Investmentsin Associatesat Cost: 95700000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Investmentsin Joint Venturesat Cost: 1587900000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 3935800000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 9545200000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 3215300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 6189600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 9404900000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 3935800000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -56500000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 1683600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 1727200000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 90081700000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 120000000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Minority Interests: -1500000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net Business Purchase And Sale: -915900000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Net Debt: 4652300000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 3104600000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Net Income: 19275000000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 19275000000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 19276500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 19275000000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 19275000000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 26125000000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 19276500000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net Intangibles Purchase And Sale: -3166000000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Net Interest Income: 54100000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: 3373700000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 24576100000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 3879300000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 54100000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: -16608400000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Net PPE: 128036000000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -23927100000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 20696800000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 229179300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 0.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 6774900000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 3896100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 1727200000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 4766100000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 39967600000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Normalized Income: 19354176670.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 23867500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Operating Income: 25376000000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Operating Revenue: 246171300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 585938609.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Other Cash Adjustment Outside Changein Cash: 64100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 18687000000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 2235900000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 267812600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 33258500000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 3784800000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -299600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 45300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: -15153200000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 1288400000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 31288000000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Payable: 8816600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Properties: 79953800000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 5480000000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 18273400000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Other Special Charges: -132300000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Payables: 47554600000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2005300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 16799600000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Pretax Income: 26125000000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 524500000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: -1969700000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of Intangibles: -3166000000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -20141000000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -24038000000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 30035100000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 118997000000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 12445800000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 1337600000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 1337600000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -56500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Research And Development: 395100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 115700000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Restructuring And Mergern Acquisition: 0.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 240130300000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of Business: 1053800000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 23514700000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 110900000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 16857600000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 23481700000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Share Issued: 585938609.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Special Income Charges: -107300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 268398500000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 229179300000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -28123330.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Tax Provision: 6848500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.26
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 756200000.00
AUROPHARMA.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -7172400000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Assets: 398899900000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 274588100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Debt: 52862100000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 268518500000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Total Expenses: 220795300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 130381400000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 183443200000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 15443600000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 115300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 2116000000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -107300000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -107300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Tradeand Other Payables Non Current: 290400000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Trading Securities: 1511500000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Work In Process: 14068300000.00
AUROPHARMA.NS balance_sheet (annual, 2023-03-31) — Working Capital: 100518900000.00
AUROPHARMA.NS income_statement (annual, 2023-03-31) — Write Off: 0.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — +Operating Expense: 110267600000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — +Total Revenue: 287045000000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 44541600000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 48167400000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -63726900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 5295100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -1232500000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Amortization: 5737700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 5737700000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Assets Held For Sale Current: 4337100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 471200000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 585938609.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Basic EPS: 54.16
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 43922700000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 49160600000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -35615000000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 3324100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 585900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 33934800000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 63251700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -2636400000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 20115700000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 13819100000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -13036800000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -8425700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 539800000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Payable: 5828400000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -2641900000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -16750700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -10210100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock: 585900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 298428000000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: 0.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 28661800000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 132362100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Assets: 242056300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 798800000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt: 41803200000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 42602000000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Deferred Taxes Liabilities: 2490100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 121991300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 2567900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Defined Pension Benefit: 10800000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation: 9181400000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 14919100000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 14919100000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 9181400000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 585938609.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Diluted EPS: 54.16
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 31729700000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 30200000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — EBIT: 46480800000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — EBITDA: 61399900000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 141700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — End Cash Position: 33854300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 151500000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: 8004200000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 45609500000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: -11269800000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -28000000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -234900000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 8176900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill: 5951500000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 40766100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 49399900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 207843800000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Gross Profit: 154682900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 34500000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Held To Maturity Securities: 893400000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Impairment Of Capital Assets: 623700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense: 2680900000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 2680900000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income: 2857600000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 2857600000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -2506500000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 2808400000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Inventories Adjustments Allowances: -22400000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Inventory: 98082300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 361580200000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -42559500000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 1516100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentsin Associatesat Cost: 97200000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentsin Joint Venturesat Cost: 1603300000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 15632400000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 9786500000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 2525300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 21349000000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 23874300000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 15632400000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -171700000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 1700500000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 2257000000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 120234900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 80000000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Minority Interests: 40000000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: 0.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 0.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Debt: 29217400000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -511400000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Net Income: 31729700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 31729700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 31689700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 31729700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 31729700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 43799900000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 31689700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Intangibles Purchase And Sale: -7811700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Net Interest Income: -39500000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 1534500000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 14613100000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 15460700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -39500000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: -11890200000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Net PPE: 144116900000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -27200500000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: -847600000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 257661900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 363500000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 12126400000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 3565600000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 2257000000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 5819300000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 64275600000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Normalized Income: 33810268950.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 24345200000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Operating Income: 44415300000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Operating Revenue: 287045000000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 585938609.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 25364300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 2803300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 297842100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 34814600000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 4683300000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -277200000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 2299600000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 364700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 2057200000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 32089100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Payable: 11303100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Properties: 115455100000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 5278400000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 29316900000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Other Special Charges: -1032700000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Payables: 55874900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2567900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 22857600000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Pretax Income: 43799900000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 232800000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: 0.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Intangibles: -7811700000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -235900000.00
AUROPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -27803300000.00
AUROPHARMA.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 32041600000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 132362100000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 14919100000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 1204200000.00
AUROPHARMA.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 1204200000.00